IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors
Status:
Active, not recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This study is to determine the safety of IRX-2 Regimen combined with Nivolumab in patients
with recurrent metastatic solid tumors. Researchers believe that this combination will have a
tolerable safety profile and will increase the response rate in comparison to Nivolumab
alone.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute